ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1403

MRI-defined Sacroiliitis in First Degree Relatives of Ankylosing Spondylitis Patients
Abstract Number: 1878

MRI-determined Intramuscular Fat Changes During Oral Glucocorticoid Treatment: Findings from a Feasibility Study
Abstract Number: 0772

MUC5B Promoter Variant and Survival in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 1696

Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis
Abstract Number: 1795

Multi-Omics Analyses Identify Metabolic Pathways That Differentiate Psoriatic Arthritis from Psoriasis
Abstract Number: 0092

Multi-omics Immune Profiling of Cytotoxic T Cells from Ankylosing Spondylitis Patients Identified a Subset of Clonally Exapnded CTLs That Evade Immune Exhaustion
Abstract Number: 2340

Multi-targeted Therapy Better in Achieving Complete Response in Lupus Nephritis: A Systematic Review and Meta-analysis
Abstract Number: 0501

Multicentre Study of Uveitis in Spondyloarthritis: Prevalence, Characteristics, and Prognosis
Abstract Number: 0640

Multidisciplinary and Multiparametric Evaluation of Sarcopenia in Patients with Systemic Sclerosis
Abstract Number: 1068

Multidisciplinary Prospective Study of Patients Treated with Immune Checkpoint Inhibitors Who Developed Rheumatic Immune-related Adverse Events
Abstract Number: 1969

Multimorbidity and PROMIS Health Outcomes in Patients with Idiopathic Inflammatory Myopathies: Analysis from the COVAD Study
Abstract Number: 1276

Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis
Abstract Number: 0849

Multiplex Profiling and Machine Learning Reveal Distinct Signatures of Circulating Cytokines Associated with Autoantibody Profiles and Disease Severity in Systemic Lupus Erythematosus
Abstract Number: 0180

Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta-analysis and Systematic Review
Abstract Number: 0750

Multispectral Optoacoustic Tomography of the Entheses Reveals Common Metabolic and Architectural Tissue Patterns in Psoriasis and Psoriatic Arthritis Independent of Inflammation

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].